BrainStorm Cell Therapeutics Presents at the 11th International Conference on Alzheimer’s and Parkinson’s Disease

NEW YORK, NY and PETACH TIKVAH, ISRAEL–(Marketwire – Mar 8, 2013) –  BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today a poster presentation of clinical and scientific data at the 11th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2013) this week in Florence, Italy (

« We are excited to be presenting our NurOwn™ technology at this important meeting, » said Alon Natanson, Chief Executive Officer of BrainStorm Cell Therapeutics. « The AD/PD Conference brings international medical professionals together for a dynamic scientific program revealing cutting-edge research and discoveries diagnosing, preventing, and treating neurodegenerative diseases. We believe that our groundbreaking data on NurOwn™ will be well received by the attendees. »

In the coming months BrainStorm will be making a number of presentations at various international medical and research conferences as the scientific communities in Europe and the US are closely following the company’s progress with its clinical development program.


About NurOwn™
NurOwn is an autologous, adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into specialized, neuron-supporting cells. These neuron-supporting cells (known as « MSC-NTF » cells) secrete neurotrophic, or nerve-growth, factors for PROTECTION of existing motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT of nerve-muscle interaction. The ability to differentiate mesenchymal stem cells into MSC-NTF cells, and confirmation of their activity and potency before transplantation, makes NurOwn a first-of-its-kind approach for treating neurodegenerative diseases. More information about NurOwn™ can be found at

About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics, Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company’s website at


BrainStorm Cell Therapeutics Inc. 
Mr. Alon Natanson
Phone: +972-3-9236384

LifeSci Advisors, LLC
Michael Rice
Founding Partner


This press release was originally posted on MarketWire. 

You can read the original article here.

Responses are currently closed, but you can trackback from your own site.

Comments are closed.